A citation-based method for searching scientific literature

Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020
Times Cited: 2







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
339
100

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Rohit Loomba, Eric Lawitz, Parvez S Mantry, Saumya Jayakumar, Stephen H Caldwell, Hays Arnold, Anna Mae Diehl, C Stephen Djedjos, Ling Han, Robert P Myers,[...]. Hepatology 2018
168
100

Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Xiao-Xue Zhu, Da-Long Zhu, Xiao-Ying Li, Ya-Lin Li, Xiao-Wei Jin, Tian-Xin Hu, Yu Zhao, Yong-Guo Li, Gui-Yu Zhao, Shuang Ren,[...]. Diabetes Obes Metab 2018
7
50

Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
Shawn E McCandless, Jack A Yanovski, Jennifer Miller, Cary Fu, Lynne M Bird, Parisa Salehi, Christine L Chan, Diane Stafford, M Jennifer Abuzzahab, David Viskochil,[...]. Diabetes Obes Metab 2017
29
50

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
Jay S Skyler, George L Bakris, Ezio Bonifacio, Tamara Darsow, Robert H Eckel, Leif Groop, Per-Henrik Groop, Yehuda Handelsman, Richard A Insel, Chantal Mathieu,[...]. Diabetes 2017
119
50

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
10
50

Fibroblast Growth Factor 21-Metabolic Role in Mice and Men.
Harald Staiger, Michaela Keuper, Lucia Berti, Martin Hrabe de Angelis, Hans-Ulrich Häring. Endocr. Rev. 2017
62
50

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Pascale Fouqueray, Valdis Pirags, Silvio E Inzucchi, Clifford J Bailey, Guntram Schernthaner, Michaela Diamant, Harold E Lebovitz. Diabetes Care 2013
22
50


EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Wenbin Zhang, Ajith Welihinda, Jordan Mechanic, Haifeng Ding, Liangcheng Zhu, Yuan Lu, Zhongping Deng, Zelin Sheng, Binhua Lv, Yuanwei Chen,[...]. Pharmacol. Res. 2011
27
50

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
Kurt Ritter, Christian Buning, Nis Halland, Christoph Pöverlein, Lothar Schwink. J. Med. Chem. 2016
46
50

GLP-1 receptor agonists: differentiation within the class.
Simeon I Taylor. Lancet Diabetes Endocrinol 2018
11
50

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
88
50

Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
Joseph Proietto, Jaret Malloy, Dongliang Zhuang, Mark Arya, Neale D Cohen, Ferdinandus J de Looze, Christopher Gilfillan, Paul Griffin, Stephen Hall, Thomas Nathow,[...]. Diabetologia 2018
6
50


Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2018
169
50

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal, Kim Henriksen. J. Pharmacol. Exp. Ther. 2019
5
50

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, James F Trotter, Angelo H Paredes, Hays L Arnold, Marcelo Kugelmas, Mustafa R Bashir, Mark J Jaros, Lei Ling,[...]. Lancet 2018
107
50

Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Xiaolan Yong, Aidong Wen, Xiangyang Liu, Haiyan Liu, Yan-Ping Liu, Nan Li, Tingting Hu, Ying Chen, Minquan Wang, Lantian Wang,[...]. Clin Drug Investig 2016
2
50

Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites.
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan,[...]. Biochem. Pharmacol. 2018
4
50


Non-alcoholic fatty liver disease and diabetes.
Jonathan M Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F Cobbold, Jeremy W Tomlinson. Metab. Clin. Exp. 2016
136
50

Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.
Shannon E Mullican, Shamina M Rangwala. Trends Endocrinol. Metab. 2018
25
50


Oral semaglutide for the treatment of type 2 diabetes.
Maka S Hedrington, Stephen N Davis. Expert Opin Pharmacother 2019
7
50

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
101
50

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Julio Rosenstock, Christopher H Sorli, Michael E Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart,[...]. Diabetes Care 2019
5
50

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg, William L Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K Schilske, David E Moller. Cell Metab. 2013
425
50




Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
André J Scheen, Nicolas Paquot, Pierre J Lefèbvre. Expert Opin Investig Drugs 2017
20
50


Glucokinase activators for diabetes therapy: May 2010 status report.
Franz M Matschinsky, Bogumil Zelent, Nicolai Doliba, Changhong Li, Jane M Vanderkooi, Ali Naji, Ramakanth Sarabu, Joseph Grimsby. Diabetes Care 2011
53
50

Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Karl Sebastian Johansson, Andreas Brønden, Filip Krag Knop, Mikkel Bring Christensen. Expert Opin Pharmacother 2020
2
50

GLP-1 and Amylin in the Treatment of Obesity.
T Jorsal, J Rungby, F K Knop, T Vilsbøll. Curr. Diab. Rep. 2016
28
50

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
Erin S Morgan, Li-Jung Tai, Nguyen C Pham, Julia K Overman, Lynnetta M Watts, Anne Smith, Shiangtung W Jung, Martin Gajdošík, Martin Krššák, Michael Krebs,[...]. Diabetes Care 2019
8
50

Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
N B Amin, N Aggarwal, D Pall, G Paragh, W S Denney, V Le, M Riggs, R A Calle. Diabetes Obes Metab 2015
14
50

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
16
50

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Vanita R Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M Lalic, Enrique C Morales Villegas, Ole K Jeppesen, Erik Christiansen, Christin L Hertz, Martin Haluzík. Diabetes Care 2019
39
50

Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E Trautmann, Marcus Hompesch, John Stewart, Christopher H Sorli. Diabetes Obes Metab 2020
3
50

Protein tyrosine phosphatase-1B in diabetes.
B P Kennedy, C Ramachandran. Biochem. Pharmacol. 2000
82
50

Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
42
50


Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
Stefano Del Prato, Jahoon Kang, Michael E Trautmann, John Stewart, Christopher H Sorli, Michael Derwahl, Alfonso Soto, Kun-Ho Yoon. Diabetes Obes Metab 2020
4
50

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
Nicole C Goodwin, Zhi-Ming Ding, Bryce A Harrison, Eric D Strobel, Angela L Harris, Melinda Smith, Andrea Y Thompson, Wendy Xiong, Faika Mseeh, Debra J Bruce,[...]. J. Med. Chem. 2017
18
50


The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo.
Yi Huan, Qian Jiang, Gang Li, Guoliang Bai, Tian Zhou, Shuainan Liu, Caina Li, Quan Liu, Sujuan Sun, Miaomiao Yang,[...]. Sci Rep 2017
5
50

FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia.
Tian Lan, Donald A Morgan, Kamal Rahmouni, Junichiro Sonoda, Xiaorong Fu, Shawn C Burgess, William L Holland, Steven A Kliewer, David J Mangelsdorf. Cell Metab. 2017
67
50

A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.
Sofie Gydesen, Sara Toftegaard Hjuler, Zenia Freving, Kim Vietz Andreassen, Nina Sonne, Lars I Hellgren, Morten Asser Karsdal, Kim Henriksen. Br. J. Pharmacol. 2017
15
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.